Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care

Access Activity

Overview / Abstract:


Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites (eg, cortical bone). Approximately 32,270 new cases of MM are diagnosed in the United States annually and 12,830 people die of the disease. Although the tumor cells remain primarily within the bone marrow, they can cause a number of complications, including localized bone destruction, anemia, decreased immunity to infection, and kidney damage. MM is primarily considered a disease of older adults, with a median age at diagnosis of 69 years. From 1975 to 2007, the incidence increased by 11.4%, and is expected to continue to rise in conjunction with the aging population. Early diagnosis is difficult because symptoms often do not appear until the malignancy is in advanced stages. The 5-year survival rate remains only 52.2%.


Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with MM.


Upon completion of this activity, participants should be able to:

1.) Identify predictive and prognostic markers that can tailor treatment selection and goals to individual patients with MM
2.) Evaluate the efficacy and safety profiles of novel therapeutic strategies for newly diagnosed and relapsed/refractory MM
3.) Assess strategies to manage treatment-related adverse events, promote adherence to therapy, and ensure patient-centered MM care


May 18, 2021


Nurse Practitioner , Nursing CNE


Online, Webinar / Webcast / Video

Credits / Hours

1.0 NCPD



Presenters / Authors / Faculty

Beth Faiman, PhD, MSN, APN-BC, AOCN® (Chairperson)
Nurse Practitioner, Department of Hematologic Oncology
Cleveland Clinic Taussig Cancer Institute

Activity Specialities / Related Topics

Adverse Drug Reactions / ADR, Diagnosis / Assessment / Patient History, Hematology, Transplant Medicine

Sponsors / Supporters / Grant Providers

This activity is supported by independent educational grants from Celgene Corporation, Sanofi Genzyme, and Karyopharm Therapeutics. Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Keywords / Search Terms

i3 Health i3 Health, multiple myeloma, MM, online CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map